Burnham signs assay development and licensing agreement with J&JPRD

The agreement is Burnham’s first broad-based partnership with a large pharmaceutical company.

Under this multi-year agreement, Burnham will provide Johnson & Johnson Pharmaceutical R&D (J&JPRD) with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.

John Reed, president and CEO of Burnham, said: “This collaboration offers great synergies. Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential.”